Recognized as pioneers in developing deep clinical AI to improve patient care for vascular and neurovascular conditions

RapidAI, the global leader in developing Artificial Intelligence (AI) and technology workflow solutions to combat life-threatening neurovascular, trauma, cardiac and vascular conditions, has been named to CB Insights’ fifth-annual Digital Health 50 (formerly Digital Health 150), a list of the 50 most promising private digital health companies of 2023.

The recognition comes amid ongoing company momentum, including the recent launch of its Edge Cloud Platform, Shonin clearance and international expansion in Japan – the second largest stroke market in the world – and receiving FDA clearance of Rapid SDH, all since its $75M Series C funding round earlier this year.

As the only platform that can support deep clinical AI, RapidAI is revolutionizing treatment planning by providing more context to medical images, including localization, quantification, characterization, visualization and tracking of potential serious conditions. RapidAI supports clinical decision making past the point of triage, empowering physicians at hospitals of all sizes and geographic locations to make faster, more accurate diagnostic and treatment decisions. RapidAI’s ability to enable efficiencies in decision making can help identify new patients, reduce time to treatment, and positively impact patient outcomes.

“Hospitals and care teams around the globe are looking for ways to get more out of their imaging and AI solutions, and this acknowledgement validates the key role RapidAI is playing in making providers more efficient, relieving burnout, increasing equity of access to advanced imaging technology, and improving care for all patients,” said Karim Karti, CEO of RapidAI. “We’re honored to be recognized for our contributions by providing an unmatched level of clinical depth across multiple disease states.”

The 2023 CB Insights’ Digital Health 50 honorees were selected from a pool of over 10,000 companies, including applicants and nominees. RapidAI was selected within the Diagnosis & Imaging category, which honored companies focused on early detection and diagnosis.

To learn more about RapidAI, please visit: https://www.rapidai.com/

About RapidAI

RapidAI is the global leader in using AI to combat life-threatening vascular and neurovascular conditions. Leading the next evolution of clinical decision-making and patient workflow, RapidAI is empowering physicians to make faster decisions for better patient outcomes. Based on intelligence gained from 10 million scans in more than 2,200 hospitals in over 100 countries, the Rapid® platform transforms care coordination, offering care teams a level of patient visibility never before possible. RapidAI – where AI meets patient care.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231212183993/en/